Impact of hemoglobin (Hb) on outcomes of adjuvant chemotherapy (ACT) with cisplatin/vinorelbine in patients (pts) with completely resected non-small cell lung cancer (NSCLC) in JBR.10.

被引：0
|
作者：
Gauthier, I
Ding, K
Winton, T
Shepherd, F
Livingston, R
Johnson, DH
Rigas, JR
Whitehead, M
Graham, B
Seymour, L
机构：
[1] Natl Canc Inst, Kingston, ON, Canada
[2] SW Oncol Grp, Seattle, WA USA
[3] Eastern Cooperat Oncol Grp, Nashville, TN USA
[4] Canc & Leukemia Grp B, Chicago, IL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：670S / 670S
页数：1
相关论文
共 50 条
  • [41] CANOPY-A: Phase III study of canakinumab (CAN) as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC)
    Garon, E. B.
    Lu, S.
    Goto, Y.
    De Marchi, P. R.
    Paz-Ares, L.
    Spigel, D. R.
    Thomas, M.
    Yang, J. C-H.
    Ardizzoni, A.
    Barlesi, F.
    Khanna, S.
    Bossen, C.
    Carbini, M.
    Yovine, A.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1414 - S1415
  • [42] Adjuvant chemotherapy in non-small cell lung cancer (NSCLC)
    Felip, E.
    Cedres, S.
    Peralta, S.
    Prat, A.
    ANNALS OF ONCOLOGY, 2007, 18 : 143 - 146
  • [43] Substantial risk affects the stage-dependent outcomes of cisplatin-based adjuvant chemotherapy for completely resected non-small cell lung cancer
    Yoshino, Ichiro
    SURGERY TODAY, 2014, 44 (02) : 302 - 306
  • [44] Substantial risk affects the stage-dependent outcomes of cisplatin-based adjuvant chemotherapy for completely resected non-small cell lung cancer
    Ichiro Yoshino
    Surgery Today, 2014, 44 : 302 - 306
  • [45] Microarray profiles and prognosis of completely resected non-small cell lung cancer (NSCLC) patients
    van Zandwijk, N
    LUNG CANCER, 2005, 49 : S10 - S10
  • [46] Vinorelbine-induced phlebitis is common in patients receiving adjuvant chemotherapy for non-small cell lung cancer (NSCLC).
    Shum, Elaine
    Halmos, Balazs
    Cheng, Haiying
    Perez-Soler, Roman
    Gucalp, Rasim A.
    Packer, Stuart H.
    Keller, Steven M.
    Bhargava, Amit
    Eng, Yoko
    Ravera, Elizabeth
    Baker, Cheryl
    Viswanathan, Shankar
    Na, Cecilia
    Gajavelli, Srikanth
    Browne, Royston
    Haigentz, Missak
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [47] FEASIBILITY STUDY OF S-1 ADJUVANT CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER
    Okumura, Shunsuke
    Sasaki, Takaaki
    Minami, Yoshinori
    Kitada, Masahiro
    Ohsaki, Yoshinobu
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1327 - S1328
  • [48] Role of Pharmacists in Completion of Adjuvant Cisplatin-Vinorelbine Chemotherapy in Japanese Patients with Non-small Cell Lung Cancer
    Morimoto, Yoshihito
    Takei, Hidefumi
    Tachibana, Keisei
    Nakazato, Yoko
    Tanaka, Ryota
    Nagashima, Yasushi
    Watanabe, Kazuhiro
    Seki, Reisuke
    Shinohara, Takao
    Kondo, Haruhiko
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2018, 138 (03): : 437 - 442
  • [49] Adjuvant lung project Italy (ALPI): the Italian/EORTC-LCCG randomised trial of adjuvant cisplatin-based chemotherapy in completely resected non-small cell lung cancer (NSCLC)
    Scagliotti, G
    LUNG CANCER, 2004, 46 : S13 - S14
  • [50] Adjuvant chemotherapy for surgically resected non-small cell lung cancer
    Heon, Stephanie
    Johnson, Bruce E.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2012, 144 (03): : S39 - S42
12345